Provided is a fluorine-containing amino acid prodrug represented by the general formula (I) obtained by converting a fluorine-containing amino acid which is a group 2 metabotropic glutamate receptor agonist into a prodrug, or a pharmaceutically acceptable salt thereof. More specifically, schizophrenia, anxiety disorders and related diseases, depression, bipolar disorder, epilepsy, developmental disorders, neuropsychiatric disorders such as sleep disorders, and drug addiction, cognitive impairment, Alzheimer's disease, Huntington's choreography Diseases associated with group 2 metabotropic glutamate receptors, such as neurological diseases such as Parkinson's disease, movement disorders associated with muscle stiffness, cerebral ischemia, brain failure, spinal cord disorder, and head disorders Provided as a therapeutic or prophylactic agent is a prodrug that enhances mucosal absorbability such as oral absorbability of a parent compound acting on a group 2 metabotropic glutamate receptor and increases the amount of in vivo exposure. [Chemical 1]グループ２代謝型グルタミン酸受容体作動薬である含フッ素アミノ酸をプロドラッグ化した一般式（Ｉ）で表される含フッ素アミノ酸プロドラッグ、又はその医薬上許容される塩を提供する。より詳細には、統合失調症、不安障害及びその関連疾患、うつ病、双極性障害、てんかん、発達障害、睡眠障害等の精神神経疾患、並びに、薬物依存症、認知障害、アルツハイマー病、ハンチントン舞踏病、パーキンソン病、筋硬直に伴う運動障害、脳虚血、脳不全、脊髄障害、頭部障害等の神経学的疾患など、グループ２代謝型グルタミン酸受容体が関与しているとされる疾患の治療剤又は予防剤として、グループ２代謝型グルタミン酸受容体に作用する親化合物の経口吸収性等の粘膜吸収性を高め、生体内暴露量を増大させるプロドラッグを提供する。【化１】
